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Abstract 
Background: Little evidence exists regarding the cost-effectiveness of self-monitoring of 
blood pressure in general and self-management of hypertension in particular.  
 
Objective: To evaluate whether self-management of hypertension was cost-effective when 
compared to usual care. 
 
Design: A Markov model-based probabilistic cost-effectiveness analysis. 
 
Data sources: Cost and utility data collected from the telemonitoring and self-management in 
hypertension trial (TASMINH2) and from the literature. 
 
Target population: UK population with mean age 66 years. 
 
Time Horizon: Lifetime 
 
Perspective: UK Health Service perspective 
 
Intervention: Self-management of hypertension including self-monitoring and self-titration of 
antihypertensives  
 
Outcome measures: Lifetime costs, quality adjusted life years (QALYs) and incremental 
cost-effectiveness ratios 
 
Results of Base-Case Analysis: In the long-term, when compared to usual care, self-
management was more effective, by 0.1290 (95% CI 0.0854, 0.1762) QALYs gained per 
patient, but also more expensive per patient albeit not significantly, (£590 (US$896) (95% CI 
£-810 to £1,903)).  The resultant incremental cost-effectiveness ratio for self-management 
was £4,576 (US$ 6,952) per QALY (95% CI: usual care dominated to £16,814), with a 99% 
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chance of the intervention being cost-effective at a willingness to pay threshold of £20,000 
(US$ 30,000) per QALY gained.  
 
Results of sensitivity analyses: These results were robust to the effect of different time 
horizons, reduced effectiveness over time from self-management and the distributional 
uncertainty in Markov model inputs.  
 
Limitation: Adverse effects were not expressly modelled but are taken into account in quality 
of life measures and were infrequent in the underlying trial. 
 
Conclusion: Self-monitoring with self-titration of antihypertensives and telemonitoring of 
blood pressure measurements not only reduces blood pressure, compared to usual care, but 
also represents a cost-effective use of health care resources. 
 
Funding: UK Department of Health Policy Research Programme, the UK National 
Coordinating Centre for Research Capacity Development and Midlands Research Practices 
Consortium. 
 
 
Clinical Trial Registration: http://www.controlled-trials.com/ISRCTN17585681/TASMINH2  
(ISRCTN17585681) 
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Introduction  
Raised blood pressure remains a key factor in determining lifetime risk of cardiovascular 
disease, the largest cause of morbidity and mortality worldwide, yet only about a half of 
people on treatment for hypertension have their blood pressure controlled to recommended 
levels.(1-3) This difficulty in achieving control is despite significant advances in the evidence 
base for both lifestyle and pharmaceutical interventions.(4;5) Therefore, there is a potentially 
important role for novel interventions to lower blood pressure, particularly in primary care, 
where most hypertension management takes place. 
 
One such approach is patient self-management, which has gained widespread use in other 
chronic conditions such as diabetes (6) and anticoagulation control.(7) Self-management 
comprising self-monitoring and self-titration of antihypertensive medication, has recently been 
shown to reduce blood pressure but prior to implementation the implications of the additional 
requirements (training, monitoring equipment) on costs and cost-effectiveness need to be 
evaluated.(8) 
 
Previous work has largely evaluated the cost-effectiveness of self-monitoring of hypertension. 
The results of these evaluations have been inconsistent and have not been extrapolated to 
the longer term. (9-15) One study reported trial costs of self-monitoring with a behavioural 
self-management intervention and then conducted an informal cost-effectiveness analysis 
with results expressed in terms of costs per life years (10). To our knowledge, no studies to 
date have examined the long-term cost-effectiveness of self-monitoring combined with self-
titration in hypertension. 
 
This study aimed to assess the long-term cost-effectiveness of self-monitoring with self-
titration of antihypertensives and telemonitoring of blood pressure measurements, hereafter 
simply referred to as self-management of hypertension or intervention, in comparison with 
usual hypertension care. A model-based probabilistic cost-effectiveness analysis was 
undertaken extrapolating from cost and utility data collected from the first major randomised 
controlled trial (RCT) of such self-management (TASMINH2).(8) 
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Methods 
Development of the cost-effectiveness model 
The long-term cost-effectiveness of self-management of hypertension compared to usual care 
in patients with treated but poorly controlled hypertension was estimated using a Markov 
model. The model was built in TreeAge Pro 2009 (16) using previously documented methods 
(17;18) Briefly, this entailed dividing a patient's possible course of disease progression into a 
number of health states with transition probabilities assigned for the movement between 
these states over a discrete time period called the Markov cycle. Long-term costs and health 
outcomes were assessed by attaching estimates of resource use and health outcomes to the 
states in the model and then running the model over a large number of cycles.  
 
In the model, the long-term progress of a hypothetical cohort of hypertensive patients moving 
along the two alternative pathways of care as received in the trial was compared. The 
methodological details of this prospective RCT are reported elsewhere.(19) Briefly, primary 
care physicians identified potential participants from among their own patients using 
electronic searches of practice clinical record systems from 24 general practices in the West 
Midlands, United Kingdom (UK) between March 2007 and May 2008. (20) To be eligible, 
patients had to be aged 35-85, have a blood pressure at baseline of over 140/90 mmHg, be 
receiving treatment for hypertension with two or fewer antihypertensive drugs and also be 
willing to self-monitor and self-titrate medication. Patients following the self-management 
pathway were trained in the use of an automated sphygmomanometer (Omron 705IT, Omron 
Healthcare Europe, Hoofddorp, Netherlands) and associated equipment to take and transmit 
blood pressure readings.(8) On the basis of their readings and following an initial consultation 
with their primary care physicians, patients could make medication changes without needing 
to re-consult. (8) For usual hypertension care, patients received an annual hypertension 
review as per UK national guidelines.(21;22) Thereafter health resources use for both groups 
was as observed in the trial, with subsequent clinical pathways designed to mirror the natural 
progression of the condition in the population (see below).  
 
 7 
 
Model-based predictions of costs and outcomes were compared for the intervention and usual 
care groups in a cost-utility analysis (CUA) from the UK National Health Service (NHS) 
perspective. This choice of cost perspective reflected the effect that the NHS budget 
constraint has on decision making by the UK National Institute for Health and Clinical 
Excellence (NICE) and was also in recognition of the fact that the burden of financing of 
healthcare in the UK falls on the NHS.  
 
Model structure and inputs 
The structure of the Markov model is shown in Figure 1. Only health states for the ‘Self-
management of hypertension’ arm are shown but these are identical to those in the ‘usual 
care’ arm. In broad terms, individual patient data were used from the TASMINH2 trial,(8) 
supplemented by the best available estimates from published sources, where necessary. The 
mean age of patients on entry into the model was 66 years.(8) The time horizon for the model 
was 35 years which was the patient lifetime assumed in the analysis. 
 
The Markov process for each arm began with the initial health state, ‘well,’ representing 
individuals with stable but poorly controlled hypertension. Patients could remain in the well 
state or move to one of five possible acute health states namely stroke, myocardial infarction 
(MI), angina, heart failure (HF) and peripheral vascular disease (PVD).(23) Individuals that 
survived an acute phase in any of the five health states naturally progressed into a chronic 
phase where quality of life was lower than in the “well” state (see table 2 for utilities). 
Individuals in a chronic health state remained in that state for the rest of their lives unless they 
died before the end of the time horizon for the model. The risk of secondary events was not 
modelled and a cycle length of one year was used.  
 
Transition probabilities governing movement between the six states were obtained from 
published sources (24-31) and are shown in table 1. In order to arrive at the annual risk rates 
of experiencing any of the five cardiovascular events used in the model, 10 year risk values 
were calculated using the Framingham equation.(31) These rates were then split between the 
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five health states by weighting the risks according to proportions obtained from D’Agostino et 
al. (23)  
 
Age-related relative risks of having a cardiovascular event following use of antihypertensive 
drugs, together with associated reductions in BP, were obtained from Law et al.(4) This 
information was then used to extrapolate from the 12 month reductions in BP recorded in the 
TASMINH2 trial (17.6mmHg and 12.2mmHg for the intervention and control arms, 
respectively (8)) to the age-related relative risks subsequently used in the model. The base 
case assumed that the 12-month difference in BP between self-management and usual care 
was maintained over the lifetime of the model, as were the costs of the intervention and this 
assumption was then tested in sensitivity analyses (see below). The extrapolated relative risk 
for coronary heart disease (CHD) was also assumed for MI, angina and HF using data on the 
breakdown of CHD events from Wood et al (32) while that for stroke was assumed for PVD as 
well. Risk rates, depicting the probability of developing a condition as well as that of dying 
from it or from other causes, were incorporated in the model as shown in table 1.  
 
Resource use and costs 
All costs are reported in UK pounds at 2009/10 unit prices and, where appropriate, were 
discounted at 3.5% as recommended by NICE.(33) Resource use and subsequent costs per 
patient obtained from the TASMINH2 trial were applied to the initial health state in the model. 
Total costs per patient in the trial were calculated as the sum of the costs of inpatient and 
outpatient visits, primary care consultations, drugs, equipment and training. Equipment and 
training costs (£230) were annuitized at 3.5% and based on a lifetime of five years.(34) 
Replacement costs for the equipment and costs of additional training were included at 5-
yearly intervals over the lifetime of the model. Equipment used by individuals who died within 
any 5-year interval was assumed to be discarded. Costs for the acute and chronic states were 
obtained from a number of other sources.(35;35-38) Costs considered over the lifetime of the 
model included costs of treatment, the intervention, consultation, and subsequent 
cardiovascular events. All cost data are shown in table 2. 
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Utility values 
All utility scores, which reflect the health-related quality of life associated with each health 
state in the model, are shown in table 2. The starting quality of life (QoL) for individuals in the 
model was assumed to be 0.82.  This was calculated as the average of the baseline EQ-5D 
scores for patients in the TASMINH2 trial.(8) Where an acute event occurred, it was assumed 
to happen approximately six months into a one year cycle; individuals stayed in that acute 
state for six months before transitioning into a chronic state. Utilities for the acute state were 
therefore applied mid-way through the one-year cycle and those for the chronic state at the 
start of the next cycle following an acute event.  Utility values for all acute and chronic health 
states were obtained from Cooper et al.(38)  
 
Analysis 
The analyses were undertaken from a UK NHS perspective and the primary result reported in 
terms of the incremental cost per quality adjusted life year (QALY) gained. A QALY is a 
measure of health obtained by adjusting a year of life for its quality or value.(34) Probabilistic 
analyses were used in the base case based on 50,000 Monte Carlo simulations. A gamma 
distribution was fitted to the costs obtained from the TASMINH2 trial.(8) Lognormal 
distributions were used for the increased risks of death from any of the conditions, for the one 
year risk of experiencing an event and for the age-dependent relative risks associated with 
each of the events. Beta distributions were used to model the probability of dying from any of 
the cardiovascular events as well as the uncertainty around the utility values. The parameters 
used for these distributions are shown in Tables 1 and 2. Deterministic analyses were also 
undertaken. 
 
A cost-effectiveness plane (CEP) and a cost-effectiveness acceptability curve (CEAC) were 
constructed.(39;40) The CEP shows the relationship between the incremental cost and 
incremental effect of one intervention relative to another while the CEAC depicts the 
probability of one intervention being more cost-effective compared to an alternative at 
different willingness-to-pay thresholds. (39)   
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Uncertainty in the model results was assessed using sensitivity analyses. These involved 
varying the time horizon for the model from a lifetime time horizon to between 5 and 30 years. 
These time periods were chosen to represent plausible points at which the cost-effectiveness 
of the intervention could be assessed. In further sensitivity analyses, the assumption 
regarding the long term effectiveness of the intervention was tested by assessing the impact 
of reductions in effectiveness after the initial year of the study: a 25% reduction in blood 
pressure lowering in the intervention arm (from 17.6mmHg  to 13.2mmHg) meant that the 
blood pressure difference between the two groups dropped from 5.4mmHg to 1mmHg, while 
a 30.7% reduction (from 17.6mmHg  to 12.2mmHg) modelled the impact of a complete loss of 
incremental effectiveness of the intervention. These reduced effects were applied at three 
time points: 1, 4 and 14 years after commencement of the intervention. Extra time points 
relating to the effect of the 30.7% reduction (at 2 and 3 years post-intervention 
commencement) were also included to show points at which the intervention became cost 
effective when assessed against the threshold of £20,000-£30,000 (US$ 30,000–
45,000)/QALY gained, which is the conventional criterion adopted by decision makers in the 
UK NHS, such as NICE.(33) 
 
Role of the Funding Source 
The authors were supported by the UK Department of Health Policy Research Programme, 
the National Institute of Health Research, Primary Care Clinical Research and Trials Unit 
(PCCRTU) and the Midlands Research Practices Consortium. The funding sources had no 
role in the design and conduct of the study; collection, management, analysis, and 
interpretation of the data; preparation, review, and approval of the manuscript; or decision to 
submit this manuscript for publication.  
 
 
Results  
The mean lifetime costs and QALYs, based on the probabilistic approach, are presented in 
Table 3. Compared to usual care, self-management of hypertension was associated with a 
trend towards higher mean costs of £590 ($896) (95% CI £-810 to £1,903) [self-management 
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£6,831 (95% CI: £5,753 to £8,310) vs usual care £6,241 (95% CI: £4,748 to £8,158)] and 
higher QALY gains of 0.1290 (95% CI 0.0854 to 0.1762) [10.5111 (95% CI: 9.9396 to 
10.9270) vs 10.3865 (95% CI: 9.7633 to 10.8415) respectively] giving an ICER of £4,576 
(US$ 6,952)/QALY gained. The 95% CI for this ICER ranged from self-management of 
hypertension dominating usual care to an upper limit of £16,814 (US$ 25,544)/QALY gained 
i.e. 95% CI: SM to £16,814. These results from the probabilistic analysis did not differ in any 
substantive way from those based on the deterministic analysis, also presented in table 3. 
 
Figures 2a and 2b present the cost-effectiveness plane (CEP) and cost-effectiveness 
acceptability curve (CEAC), respectively, comparing self-management of hypertension to 
usual care when distributional uncertainty was incorporated. The CEP in figure 2a shows the 
joint distribution of the mean incremental costs and mean QALYs gained with most results in 
the north-east and south-east quadrants. The CEAC in figure 2b shows that the probability of 
self-management of hypertension being cost-effective compared to usual care was at least 
99% if decision makers were willing to pay at least £20,000 (US$ 30,000) per QALY-gained. 
(39) At lower thresholds, however, the probability of the intervention being cost-effective 
compared to the control was lower, dropping to 50% at around £5,000 (US$ 7,596) per 
QALY-gained.  
 
Table 3 shows that the ICERs for all time horizons considered were below £20,000 (US$ 
30,000) per QALY gained. The other sensitivity analyses conducted involved modelling a 
declining impact of the intervention on BP reduction (Table 4). When a 25% decline in 
effectiveness of the intervention was applied 1, 4 and 14 years after commencement of the 
intervention,, this resulted in ICERs of £16,027 (95% CI: SM to £67,291), £10,587 (95% CI: 
SM to £48,723) and £6,074 (95% CI: SM to £23,504) per QALY gained, respectively. When 
no difference between the two groups in terms of effectiveness was assumed (i.e. when a 
30.7% decline in effectiveness of the intervention was applied), the following ICERs were 
obtained at 1, 2, 3, 4 and 14 years after commencement of the intervention, respectively: 
£36,278 (95% CI: SM to £515,176), £23,964 (95% CI: SM to £174,573), £18,477 (95% CI: 
SM to £99,440), £15,376 (95% CI: SM to £110,610) and £6,705 (95% CI: SM to £26,982).  
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Discussion 
Statement of principal findings 
The primary analysis shows that self-monitoring and self-titration of antihypertensive 
medication is more cost-effective than usual hypertension care, provided decision makers are 
willing to pay at least £4,500 (US$ 6,800) per QALY which is well within the cost-effectiveness 
criteria applied in the UK NHS.(33) Despite the intervention being more costly than the 
control, it was associated with better quality of life due to reduced cardiovascular events. No 
evidence was found that self-management of hypertension was associated with deleterious 
direct effects on quality of life. (8) The main driver of benefit was a decline in the number of 
cardiovascular events associated with self-management.  
 
Varying the time horizons of the model from the life time (35 years) period used in the base 
case analysis and assuming a threshold of £20,000-30,000 (US$ 30,000–
45,000)/QALY(33;41) showed that self-management of hypertension was still more cost-
effective than usual care at all time periods. Similarly, provided the effects of blood pressure 
reduction observed (5.4 mmHg systolic) lasted at least 2 years, the intervention was cost 
effective. Furthermore, the intervention remained cost-effective after incorporating 
distributional uncertainty around the inputs used in the Markov model.  
 
Strengths and limitations 
A strength of this the study was the incorporation of cost and outcome data from the first 
major randomised controlled trial of self-management which had high levels of follow up and 
data capture.(8) The use of a Markov model overcame limitations associated with within-trial 
analyses due to the short time scale which makes it difficult to observe or model effects on 
long term events. It was thus possible to use generalisable data to assess the long term cost-
effectiveness beyond the trial period and model cardiovascular events and mortality.  
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Adverse effects, such as anxiety or drug side effects, were not modelled as robust data on the 
consequences of these on quality of life were not available, although no difference in anxiety 
between groups was seen in the trial.(8) Additional costs of monitoring potential side effects 
were captured by the primary care resource data collection. A potential weakness was that 
effectiveness of the intervention after the year of the study was unknown: the blood pressure 
curves were still diverging at that point. (8) Other studies have found persisting differences in 
outcome despite cessation of interventions.(42) The base case therefore assumed that the 
effects of the intervention persisted after the year of study. Sensitivity analyses modelled the 
effect of various potential reductions in efficacy of the intervention. The results remained 
robust to such reduction in efficacy, provided that some element of effectiveness was 
maintained for at least an additional 12 months after the initial year of intervention.  
 
While the Framingham risk score (31) is not based on contemporary data, it is still the 
recommended and most widely used system. (43) Further, any inaccuracies in the equation 
should not have affected the results as cardiovascular risk was estimated in the same way for 
both intervention and control but may have reduced the size of the ICERs observed. Data on 
quality of life for the different health states came from published sources which may have led 
to some variability in terms of the way QALYs were calculated. Again, because these were 
applied to both groups, biases would have been reduced.  Finally, the model has the 
structural limitation of not considering secondary events. This is a conservative assumption as 
reduction of blood pressure would be expected to reduce these in addition to the primary 
events considered hence self-management may be more cost effective than found.  
 
Comparisons with other studies 
This is the first economic analysis of self-monitoring and self-titration of hypertensive 
medication. A US randomised trial comparing usual care with twice weekly self-monitoring 
found a reduction in costs but not blood pressure in the intervention group. However the 
increased cost of medical care in the US and the age of the study mean that these results are 
not immediately transferable outside of that setting.(9) Reed et al found that a tailored 
behavioural self-management intervention combined with home blood pressure monitoring led 
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to statistically and clinically significant reductions in blood pressure but raised costs to the 
health-care system.(10) An informal estimate with a shorter time horizon of 12 years 
estimated an ICER of approximately $23,000 per life-year saved  (10) A trial of self-monitoring 
in practice waiting rooms found that this intervention was not significantly more expensive 
than usual care.(11) Fukunaga established that self-monitoring of hypertension was cost-
effective, although this was in terms of the detection of ‘white coat’ hypertension.(12) A 
Danish study found that the cost savings of home telemonitoring of blood pressure due to 
lower consultation and medication costs were negated by the cost of the telemonitoring 
equipment with uncertainty around the cost effectiveness results.(13) A final study comparing 
cost-effectiveness of different adherence-improving interventions for antihypertensive and 
lipid-lowering treatment found that self-monitoring, in combination with reminders and 
educational materials, was more cost-effective than usual care but less cost-effective than 
pharmacist/nurse management. (14) 
 
In other clinical areas, economic analyses have reached varying conclusions: self-
management of anticoagulation was not cost-effective under conventional criteria due to 
increased costs with equivalent efficacy, (38;44) whereas self-management of asthma was 
associated with both increased effectiveness and lower costs.(45) Richardson and colleagues 
showed that a generic, lay administered self-management course for chronic disease was 
cost-effective.(15) Uncertainties in the data underline the importance of accompanying 
implementation of self-management with ongoing cost-effectiveness evaluation to ensure that 
the results are replicated outside of trial conditions. 
 
Clinical Implications 
The introduction of new technologies into health systems requires robust evidence of both 
effectiveness and cost-effectiveness. Previous work has shown the former (8) and this paper 
provides data on the latter which should encourage commissioners of health to consider the 
utilisation of self-management of hypertension in daily practice. Whilst self-management may 
only be appropriate for a minority of individuals with hypertension, the numbers of people 
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affected both in the UK (2) and worldwide (46) mean that many millions of people could 
benefit from the implementation of this technology. 
 
Conclusions 
The results of this model-based economic evaluation suggest that self-monitoring with self-
titration of antihypertensives is a cost-effective strategy in the long term, resulting in QALY 
gains as well as lower blood pressure (8). Self-management of hypertension represents an 
important new addition to the management of hypertension in primary care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16 
 
Acknowledgements 
The authors would like to acknowledge the particular input of Miriam Banting and that of trial 
secretaries Amanda Davies and Sheila Bailey. The Departments of Primary Care in 
Birmingham and Oxford also receive funding as founder members of the NIHR National 
School for Primary Care Research. 
 
Approval 
This study was approved by an Institutional Review Board 
 
Contributorship 
RJM had the original idea for the study and gained funding in collaboration with JM, SB, RH, 
PL, BW and FDRH. Data for the trial were collected by the research team supervised by EB 
and RJM.  BK undertook the analyses and wrote the first draft supervised by SB and SJ.  
Subsequent drafts were contributed to by all authors who have approved the final version.  
RJM will act as guarantor. 
 
 
Disclosures 
None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17
Reference List 
 
 1.  Joint Health Surveys Unit. Health Survey for England 2006. London: HMSO; 2006. 
 2.  NHS Information Centre. Quality and Outcomes Framework 2008/09. Online GP 
practice results database; 2008. Accessed at http://www.ic.nhs.uk/statistics-and-data-
collections/audits-and-performance/the-quality-and-outcomes-framework/the-quality-
and-outcomes-framework-2008-09 on 11 March 2012.  
 
 3.  Allen N, Berry JD, Ning H, Van HL, Dyer A, Lloyd-Jones DM. Impact of blood 
pressure and blood pressure change during middle age on the remaining lifetime risk 
for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 
2012; 125: 37-44. 
 4.  Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention 
of cardiovascular disease: meta-analysis of 147 randomised trials in the context of 
expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665. 
 5.  Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV et al. 
Lifestyle interventions to reduce raised blood pressure: a systematic review of 
randomized controlled trials. J Hypertens. 2006; 24: 215-33. 
 6.  McAndrew L, Schneider SH, Burns E, Leventhal H. Does patient blood glucose 
monitoring improve diabetes control? A systematic review of the literature. Diabetes 
Educ. 2007; 33: 991-1011. 
 7.  Levi M. Self-management of anticoagulation. Expert Rev Cardiovasc Ther. 2008; 6: 
979-85. 
 8.  McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S et al. 
Telemonitoring and self-management in the control of hypertension (TASMINH2): a 
randomised controlled trial. Lancet. 2010; 376: 163-72. 
 9.  Soghikian K, Casper SM, Fireman BH, Hunkeler EM, Hurley LB, Tekawa IS et al. 
Home blood pressure monitoring. Effect on use of medical services and medical care 
costs. Med Care. 1992; 30: 855-65. 
 10.  Reed SD, Li Y, Oddone EZ, Neary AM, Orr MM, Grubber JM et al. Economic 
evaluation of home blood pressure monitoring with or without telephonic behavioral 
self-management in patients with hypertension. Am J Hypertens. 2010; 23: 142-8. 
 11.  McManus RJ, Mant J, Roalfe A, Oakes RA, Bryan S, Pattison HM et al. Targets and 
self monitoring in hypertension: randomised controlled trial and cost effectiveness 
analysis. BMJ. 2005; 331: 493. 
 12.  Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Obara T et al. Cost-
effectiveness of the introduction of home blood pressure measurement in patients with 
office hypertension. J Hypertens. 2008; 26: 685-90. 
 13.  Madsen LB, Christiansen T, Kirkegaard P, Pedersen EB. Economic evaluation of 
home blood pressure telemonitoring: a randomized controlled trial. Blood Press. 2011; 
20: 117-25. 
 14.  Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L. The 
modeled lifetime cost-effectiveness of published adherence-improving interventions for 
antihypertensive and lipid-lowering medications. Value Health. 2010; 13: 685-94. 
 18
 15.  Richardson G, Sculpher M, Kennedy A, Nelson E, Reeves D, Roberts C et al. Is 
self-care a cost-effective use of resources? Evidence from a randomized trial in 
inflammatory bowel disease. J Health Serv Res Policy. 2006; 11: 225-30. 
 16.  TreeAge Software. TreeAge Pro 2009 Suite. Williamstown, MA: TreeAge Software, 
Inc.; 2009. 
 17.  Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical 
guide. Med Decis Making. 1993; 13: 322-38. 
 18.  Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 
1983; 3: 419-58. 
 19.  McManus RJ, Bray EP, Mant J, Holder R, Greenfield S, Bryan S et al. Protocol for a 
randomised controlled trial of telemonitoring and self-management in the control of 
hypertension: telemonitoring and self-management in hypertension. 
[ISRCTN17585681]. BMC Cardiovasc Disord. 2009; 9: 6. 
 20.  McManus RJ, Ryan R, Jones M, Wilson S, Hobbs FR. How representative of primary 
care are research active practices? Cross-sectional survey. Fam Pract. 2008; 25: 56-
62. 
 21.  British Medical Association. British Medical Association and NHS Employers. Quality 
and Outcomes Framework guidance, 3rd revision. Accessed at 
http://www.bma.org.uk/employmentandcontracts/independent_contractors/quality_outc
omes_framework/qof0309.jsp on 14 October 2011. 
 22.  National Institute for Clinical Excellence. CG34 Hypertension (persistently high 
blood pressure) in adults - NICE guideline. Accessed at 
http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10986  on 24 February 2012 
 23.  D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. 
General cardiovascular risk profile for use in primary care: the Framingham Heart 
Study. Circulation. 2008; 117: 743-53. 
 24.  National Clinical Guideline Centre. Unstable Angina and NSTEMI: the Early 
Management of Unstable Angina and Non-ST-Segment-Elevation Myocardial Infarction. 
(CG94).  London: Royal College of Physicians; 2010. 
 
 25.  de GF, Khaw KT, Cowie MR, Sutton GC, Ferrari R, Poole-Wilson PA. Incidence and 
outcome of persons with a clinical diagnosis of heart failure in a general practice 
population of 696,884 in the United Kingdom. Eur J Heart Fail. 2005; 7: 295-302. 
 26.  Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU et 
al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J 
Clin Epidemiol. 2001; 54: 1244-50. 
 27.  Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, 
natural history and cardiovascular events in symptomatic and asymptomatic peripheral 
arterial disease in the general population. Int J Epidemiol. 1996; 25: 1172-81. 
 28.  Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC et al. 
Improving survival in the 6 months after diagnosis of heart failure in the past decade: 
population-based data from the UK. Heart. 2009; 95: 1851-6. 
 29.  Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA. Coronary event 
and case fatality rates in an English population: results of the Oxford myocardial 
infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. 
Heart. 1998; 80: 40-4. 
 19
 30.  Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of 
acute cerebrovascular disease in the community: the Oxfordshire Community Stroke 
Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of 
cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol 
Neurosurg Psychiatry. 1990; 53: 16-22. 
 31.  Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk 
profiles. Am Heart J. 1991; 121: 293-8. 
 32.  Wood D, Kotseva K, Fox K, Bakhai A, Bowker T. Coronary Heart Disease. In: 
Stevens A, Raftery J, Mant J, Simpson S, eds. Health Care Needs Assessment: The 
Epidemiologically Based Needs Assessment Reviews. 2nd edn. Abingdon: Radcliffe 
Medical Press Ltd; 2004: 373-448. 
 33.  National Institute for Clinical Excellence (NICE). Guide to the Methods of 
Technology Appraisal.  London: NICE; 2004.  
 34.  Drummond MF, Sculpher MJ, O'Brien B, Stoddart GL, Torrance GW. Methods for 
the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press; 
2005. 
 35.  Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai  A et al. A Cost 
Effectiveness Model Comparing Alternative Management Strategies for the Use of 
Glycoprotein IIB/IIIA Anatagonists in Non-St-Elevation Acute Conorary Syndrome. York: 
Center for Health Economics. 2004.  
 
 36.  Department of Health. NHS reference costs 2008-2009. Accessed at 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndG
uidance/DH_111591 on 3 March 2012. 
 37.  Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United 
Kingdom. Pharmacoeconomics. 2003; 21 Suppl 1: 43-50. 
 38.  Cooper A, Nherera L, Calvert N, O'Flynn N, Turnbull N, Robson J et al. Clinical 
Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment 
and the primary and secondary prevention of cardiovascular disease.  London: National 
Collaborating Centre for Primary Care and Royal College of General Practitioners. 
2008. 
 39.  Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis 
Making. 1990; 10: 212-4. 
 40.  Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of 
healthcare interventions. Health Technol Assess. 1999; 3: 1-134. 
 41.  Department of Health. NHS Reference Costs 2007-08. Accessed at 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndG
uidance/DH_098945 on 28 February 2012.  
 
 42.  Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R et al. Effects 
on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for 
about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 
2011; 378: 2013-20. 
43.  Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E et al. 
Framingham Risk Score and Alternatives for Prediction of Coronary Heart Disease in 
Older Adults. PLoS.One. 2012; 7(3): e34287. 
 20
 44.  Jowett S, Bryan S, Murray E, McCahon D, Raftery J, Hobbs FD et al. Patient self-
management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J 
Haematol. 2006; 134: 632-9. 
 45.  Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P et al. 
Randomised comparison of cost effectiveness of guided self management and 
traditional treatment of asthma in Finland. BMJ. 1998; 316: 1138-9. 
 46.  World Health Organisation. Global Health Risks: Mortality and burden of disease 
attributable to selected major risks. Geneva: WHO Press; 2009. 
 47.  Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. 
Oxford: Oxford University Press; 2006. 
 
 
 
 21 
         
   
 
Table 1.  Estimates of risk rates, probabilities & distributions used in the reference case and sensitivity analyses 
____________________________________________________________________________________________________________________ 
 
Description      Point estimate* Distribution†  Source                                           
        
Risks & probabilities  
Increased risk of death from Angina   2.19 (2.05, 2.33) Lognormal   NCGC (2010) (24) 
Increased risk of death from Heart Failure (HF)  2.17 (1.96, 2.41) Lognormal  de Guili et al (2005) (25)  
Increased risk of death from Myocardial Infarction (MI) 2.68 (2.48, 2.91) Lognormal   Bronnum-Hansen et al (2001) (26)  
Increased risk of death from Peripheral vascular  
disease (PVD)      2.44 (1.59, 3.74) Lognormal  Leng (1996) (27)  
Increased risk of death from stroke   2.72 (2.59, 2.85) Lognormal  Bronnum-Hansen et al (2001) (26) 
 
1 year risk of Angina‡     0.008 (0.004, 0.012) Lognormal  Anderson et al (1991) (31) 
1 year risk of HF‡     0.002 (0.001, 0.004) Lognormal  Anderson et al (1991) (31) 
1 year risk of MI‡     0.005 (0.003, 0.009) Lognormal  Anderson et al (1991) (31) 
1 year risk of PVD‡     0.004 (0.002, 0.006) Lognormal  Anderson et al (1991) (31)  
1 year risk of stroke‡     0.004 (0.002, 0.006) Lognormal  Anderson et al (1991) (31) 
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Relative risks of angina, HF & MI events by age (Self-monitoring arm)§, 
66-69 years      0.58 (0.52, 0.63) Lognormal  Law et al (4)  & TASMINH2(8) 
70-79 years      0.64 (0.59, 0.69) Lognormal  Law et al (4)  & TASMINH2(8) 
>79 years      0.70 (0.66, 0.74) Lognormal  Law et al (4)  & TASMINH2(8) 
 
Relative risks of PVD & stroke events by age (Self-monitoring arm)|| 
66-69 years      0.47 (0.41, 0.54) Lognormal  Law et al (4)  & TASMINH2(8) 
70-79 years      0.54 (0.47, 0.60) Lognormal  Law et al (4)  & TASMINH2(8) 
>79 years      0.70 (0.66, 0.74) Lognormal  Law et al (4)  & TASMINH2(8) 
 
Relative risks of angina, HF & MI events by age (Usual care arm)§, 
66-69 years      0.69 (0.63, 0.74) Lognormal  Law et al (4)  & TASMINH2(8) 
70-79 years      0.74 (0.69, 0.79) Lognormal  Law et al (4)  & TASMINH2(8) 
>79 years      0.79 (0.74, 0.83) Lognormal  Law et al (4)  & TASMINH2(8) 
 
Relative risks of PVD & stroke events by age (Usual care arm)|| 
66-69 years      0.60 (0.54, 0.67) Lognormal  Law et al (4)  & TASMINH2(8) 
70-79 years      0.66 (0.60, 0.72) Lognormal  Law et al (4)  & TASMINH2(8) 
>79 years      0.79 (0.74, 0.83) Lognormal  Law et al (4)  & TASMINH2(8) 
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Probability of death from HF    0.17 [r=68, n=396]¶ Beta   Mehta et al (2009) (28)  
Probability of death from MI    0.52 [r=351, n=675]¶ Beta   Volmink et al (1998) (29) 
Probability of death from stroke    0.23 [r=125, n=545]¶ Beta   Bamford et al (1990) (30) 
____________________________________________________________________________________________________________________ 
* Figures in round parentheses are 95 % Confidence interval limits                             † Distributions used in probabilistic sensitivity analysis 
‡ These baseline risk values were calculated from 10 year risk values  in Anderson et al (1991) (31) and split among 5 disease using probabilities from D’Agostino et al (2008) (23) 
§,The relative risk for having a coronary heart disease (CHD) event was also applied to angina, HF and MI events. 
||The relative risk for having a stroke event was also applied to PVD events. 
§, || Age-related relative risks were extrapolated from Law et al (2009) (4) based on 12 month BP reductions of 17.6mmHg in the intervention arm and 12.2mmHg in the control arm (from TASMINH2 
trial(8)). BP reduction in both arms was assumed to be maintained over the lifetime of the model. 
¶Figures in squared parentheses are occurrences (r) and population size (n). 
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Table 2.  Estimates of costs, utilities & distributions used in the reference case and sensitivity analyses 
__________________________________________________________________________________________________ 
Description      Point estimate  Distribution*  Source    _  
      
Costs for the initial (well) health state (UK £)†  
Self–monitoring arm     £475 (413, 597)‡, Gamma  TASMINH2 trial (8) 
SE=27   
 
Usual care arm      £370 (239, 393)‡ Gamma  TASMINH2 trial (8) 
SE=47   
  
Costs for acute disease health states (UK £) 
Angina       £2,521   Gamma§  Palmer et al (2004) (35)  
Heart Failure (HF)     £1,860   Gamma§  Department of Health (2010) (36)  
Myocardial Infarction (MI)    £1,763   Gamma§  Palmer et al (2004) (35)  
Peripheral vascular disease (PVD)   £1,546   Gamma§  Department of Health (2010)  (36)) 
Stroke       £8,316   Gamma§  Youman et al (2003) (37) 
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Costs for long-term (chronic) disease health states (UK £) 
Angina       £556   Gamma§  Cooper et al (2008) (38)  
HF       £556   Gamma§  Cooper et al (2008) (38) 
MI       £556   Gamma§  Cooper et al (2008) (38) 
PVD       £285   Gamma§  Cooper et al (2008) (38) 
Stroke       £2,555   Gamma§  Youman et al (2003) (37) 
 
Utilities for initial (well) health state  
Self–monitoring arm     0.82|| (0.212)¶         Beta   TASMINH2 (8) 
Usual care arm      0.82II (0.212)¶         Beta    TASMINH2 (8)  
 
Utilities for acute disease health states 
Angina       0.77 (0.038)¶        Beta   Cooper et al (2008) (38) 
HF       0.68 (0.020)¶        Beta   Cooper et al (2008) (38) 
MI       0.76 (0.018)¶        Beta   Cooper et al (2008) (38) 
PVD       0.90 (0.020)¶        Beta   Cooper et al (2008) (38) 
Stroke       0.63 (0.040)¶        Beta   Cooper et al (2008) (38) 
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Utilities for long-term (chronic) disease health states 
Angina     0.88 (0.018)¶       Beta  Cooper et al (2008) (38) 
HF      0.68 (0.020)¶        Beta  Cooper et al (2008) (38) 
MI     0.88 (0.018)¶        Beta  Cooper et al (2008) (38) 
PVD     0.90 (0.020)¶        Beta   Cooper et al (2008) (38) 
Stroke     0.63 (0.040)¶        Beta  Cooper et al (2008) (38) 
 
* Distributions used in probabilistic sensitivity analysis  
† Total costs included costs of drugs, outpatient visits, inpatient visits, GP visits and the intervention (equipment and training). The cost difference between self-monitoring and 
usual care was driven by cost of the intervention. 
‡ 95% confidence interval                
§ As only point estimates were obtained for these costs, the standard error was assumed to be equal to the mean as has been done elsewhere (38;47).   
|| Average of the EQ-5D scores for the intervention and control arms in the TASMINH2 trial  ¶ Standard error 
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Table 3. Cost-effectiveness results (Base case based on probabilistic analysis, sensitivity analysis involving changing time horizons and 
deterministic analysis)  
 
Time 
Horizon
 
Costs/QALYs 
 
Intervention group 
 
Control (Usual Care) 
group 
 
Difference 
 
 
ICER* 
(95% CI†) 
 
Base case results – Probabilistic Analysis 
Mean total health care costs 
(95% CI†) 
£6,831 
(£5,753 to £8,310) 
£6,241 
(£4,748 to £8,158) 
£590 
(£-810 to £1,903) 
 
Life 
time Mean QALYs gained 
(95% CIb) 
10.5155 
(9.9396 to 10.9270) 
10.3865 
(9.7633 to 10.8415) 
0.1290 
(0.0854 to 0.1762) 
 
£4,576 
(SM‡ to £16,814) 
 
Changing the time horizon – Probabilistic Analysis 
Mean total health care costs 
(95% CI†) 
£6,750 
(£5,683 to £8,223) 
£6,182 
(£4,710 to £8,089) 
£568 
(£-834 to £1,886) 
 
30 
years Mean QALYs gained 
(95% CI†) 
10.3984 
(9.8572 to 10.7850) 
10.2770 
(9.6900 to 10.7058) 
0.1214 
(0.0793 to 0.1676) 
 
£4,677 
(SM‡ to £17,785) 
 28 
         
   
 
 
 
 
Mean total health care costs 
(95% CI†) 
£6,514 
(£5,479 to £7,938) 
£5,983 
(£4,535 to £7,814) 
£531 
(£-807 to £1,810) 
 
25 
years Mean QALYs gained 
(95% CI†) 
10.0720 
(9.6059 to 10.3910) 
9.9682 
(9.4592 to 10.3238) 
0.1038 
(0.0672 to 0.1465) 
 
£5,116 
(SM‡ to £19,970) 
Mean total health care costs 
(95% CI†) 
£5,999 
(£5,051 to £7,065) 
£5,540 
(£4,209 to £7,231) 
£459 
(£-803 to £1,635) 
 
20 
years Mean QALYs gained 
(95% CI†) 
9.3647 
(9.0263 to 9.5966) 
9.2869 
(8.9146 to 9.5473) 
0.0779 
(0.0494 to 0.1119) 
 
£5,897 
(SM‡ to £24,177) 
Mean total health care costs 
(95% CI†) 
£5,091 
(£4,300 to £6,185) 
£4,747 
(£3,616 to £6,166) 
£344 
(£-745 to £1,367) 
 
15 
years Mean QALYs gained 
(95% CI†) 
8.1324 
(7.9251 to 8.2696) 
8.0835 
(7.8535 to 8.2389) 
0.0489 
(0.0308 to 0.0716) 
 
£7,040 
(SM‡ to £32,226) 
Mean total health care costs 
(95% CI†) 
£3,744 
(£3,177 to £4,494) 
£3,545 
(£2,719 to £4,560) 
£200 
(£-641 to £996) 
 
10 
years Mean QALYs gained 
(95% CI†) 
6.2712 
(6.1771 to 6.3334) 
6.2473 
(6.1422 to 6.3184) 
0.0239 
(0.0151 to 0.0349) 
 
£8,372 
(SM‡ to £47,466) 
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* ICER – Incremental cost-effectiveness ratio      † CI – confidence interval 
‡ Where the acronym for the self-management of hypertension arm (SM) is given instead of an ICER, it means that SM dominates usual care i.e. less costly and more effective 
 
 
 
Mean total health care costs 
(95% CI†) 
£1,962 
(£1,666 to £2,349) 
£1,949 
(£1,502 to £2,498) 
£14 
(£-474 to £465) 
 
5 years 
Mean QALYs gained 
(95% CI†) 
3.6441 
(3.6206 to 3.6592) 
3.6377 
(3.6114 to 3.6551) 
0.0064 
(0.0041 to 0.0092) 
 
£2,131 
(SM‡ to £18,845) 
 
Deterministic Analysis 
 
Mean total health care costs 
 
£6,824 
 
£6,235 
 
£589  
Life 
time 
Mean QALYs gained 10.5458 10.4176 0.1282 
 
£4,597 
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. Table 4. Cost-effectiveness results of declining impact of self-monitoring on BP reduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
Horizon 
 
Costs/QALYs 
 
Intervention group 
 
Control (Usual Care) 
group 
 
Difference 
 
 
ICER* 
(95% CI†) 
 
25% decline‡ in impact of intervention on BP reduction applied 1 year after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,883 
(£5,750 to £8,451) 
£6,245 
(£4,749 to £8,111) 
£638 
(£-767 to £1,953) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4284 
(9.8365 to 10.8633) 
10.3886 
(9.7681 to 10.8444) 
0.0398 
(0.0191 to 0.0683) 
 
£16,027 
(SM|| to £67,291) 
 
25% decline‡  in impact of intervention on BP reduction applied 4 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,872 
(£5,757 to £8,440) 
£6,242 
(£4,738 to £8,150) 
£629 
(£-768 to £1,942) 
 
Life 
time  Mean QALYs gained 
(95% CI†) 
10.4480 
(9.8443 to 10.8696) 
10.3885 
(9.7611 to 10.8417) 
0.0594 
(0.0278 to 0.0827) 
 
£10,587 
(SMI| to £48,723) 
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25% decline‡  in impact of intervention on BP reduction applied 14 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,857 
(£5,757 to £8,325) 
£6,249 
(£4,748 to £8,131) 
£608 
(£-789 to £1,918) 
 
Life 
time  Mean QALYs gained 
(95% CI†) 
10.4862 
(9.9000 to 10.9028) 
10.3861 
(9.7617 to 10.8420) 
0.1001 
(0.0609 to 0.1383) 
 
£6,074 
(SM|| to £23,504) 
 
30.7% decline§ in impact of intervention on BP reduction applied 1 year after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6.893 
(£5,755 to £8,508) 
£6,242 
(£4,754 to £8,137) 
£652 
(£-729 to £1,965) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4058 
(9.8132 to 10.8376) 
10.3878 
(9.7657 to 10.8381) 
0.0180 
(-0.0005 to 0.0474) 
 
£36,278 
(SM|| to £515,176) 
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30.7% decline§ in impact of intervention on BP reduction applied 2 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,888 
(£5,749 to £8,455) 
£6,246 
(£4,746 to £8,107) 
£642 
(£-749 to £1,959) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4137 
(9.8184 to 10.8501) 
10.3869 
(9.7596 to 10.8445) 
0.0268 
(0.0056 to 0.0589) 
 
£23,964 
(SM|| to £174,573) 
 
30.7% decline§ in impact of intervention on BP reduction applied 3 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,883 
(£5,759 to £8,436) 
£6,237 
(£4,744 to £8,139) 
£646 
(£-779 to £1,960) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4246 
(9.8273 to 10.8530) 
10.3896 
(9.7575 to 10.8412) 
0.0350 
(0.0117 to 0.0697) 
 
£18,477 
(SM|| to £99,440) 
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* ICER – Incremental cost-effectiveness ratio     † CI – confidence interval 
‡ A 25% decline in the impact of the intervention (from 17.6mmHg  to 13.2mmHg) meant that the difference in the effects between the two groups dropped from 5.4mmHg to 
1mmHg i.e. 12 month BP reduction in the usual care arm was 12.2mmHg.  
 
30.7% decline§ in impact of intervention on BP reduction applied 4 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,886 
(£5,740 to £8,461) 
£6,245 
(£4,739 to £8,151) 
£641 
(£-765 to £1,953) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4289 
(9.8360 to 10.8530) 
10.3872 
(9.7695 to 10.8430) 
0.0417 
(0.0100 to 0.0666) 
 
£15,376 
(SM|| to £110,610) 
 
30.7% decline§ in impact of intervention on BP reduction applied 14 years after commencement of intervention 
 
Mean total health care costs 
(95% CI†) 
£6,855 
(£5,753 to £8,367) 
£6,245 
(£4,737 to £8,122) 
£611 
(£-796 to £1,933) 
 
Life 
time Mean QALYs gained 
(95% CI†) 
10.4780 
(9.8947 to 10.8981) 
10.3890 
(9.7630 to 10.8465) 
0.0911 
(0.0516 to 0.1317) 
 
£6,705 
(SM|| to £26,982) 
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§ A 30.7% decline in the impact of the intervention (from 17.6mmHg to 12.2mmHg) implied that there was no difference at all between the two groups in terms of effectiveness 
as the 12 month BP reduction in the usual care arm was 12.2mmHg. 
|| Where the acronym for the self-management of hypertension arm (SM) is given instead of an ICER, it means that SM dominates usual care i.e. less costly and more effective. 
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Figure legends 
Figure 1: Markov model structure 
Figure 1 shows the structure of the Markov model used to conduct the cost-effectiveness 
analysis. Only health states for the ‘Self-management of hypertension’ arm are shown but 
these are identical to those in the ‘usual care’ arm. [+] means ‘same structure but with 
appropriate changes in parameter estimates’. The Markov process for each arm began with 
the initial health state, ‘well,’ representing individuals with stable but poorly controlled 
hypertension. Patients could remain in the well state or move to one of five possible acute 
health states namely stroke, myocardial infarction (MI), angina, heart failure (HF) and 
peripheral vascular disease (PVD). Individuals that survived an acute phase in any of the five 
health states naturally progressed into a chronic phase. Individuals in a chronic health state 
remained in that state for the rest of their lives unless they died before the end of the time 
horizon for the model.  
 
Figure 2: Cost-effectiveness plane of self-management of hypertension versus usual 
care and the Cost-effectiveness acceptability curve of self-management of 
hypertension versus usual care 
 
Figure 2a is a cost-effectiveness plane showing the relationship between the incremental cost 
and incremental QALYs of self-management of hypertension to usual care. It shows that most 
results are in the north-east and south-east quadrants.  
 
Figure 2b depicts the cost-effectiveness acceptability curve of self-management of 
hypertension versus usual care. It shows that the probability of self-management of 
hypertension being cost-effective compared to usual care was at least 99% if decision makers 
were willing to pay at least £20,000 (US$ 30,000) per QALY-gained. This probability dropped 
to 50% at around £5,000 (US$ 7,596) per QALY-gained. 
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Figure 2 
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Figure 2b 
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